Literature DB >> 9607209

Renal involvement in Henoch-Schönlein purpura: a multivariate analysis of prognostic factors.

Y Kaku1, K Nohara, S Honda.   

Abstract

This study is the first report in which the relationship between the progression of renal involvement in Henoch-Schönlein purpura (HSP) and various factors was evaluated using a multivariate analysis. Sixty-five (33.5%) of 194 patients with HSP developed renal involvement from three days to 17 months after the onset of the disease. The plasma coagulation factor XIII (F XIII) activity of 97 patients was examined, and 51 (54.3%) of them showed a decreased activity. A univariate analysis showed that an age at the onset of more than seven years, persistent purpura and a decreased F XIII activity all increased the risk of developing renal involvement. A Cox regression model analysis indicated severe abdominal symptoms, persistent purpura and decreased F XIII activity to be significant risk factors and their hazard ratios were 3.26, 11.53 and 2.27, respectively. Corticosteroid treatment had a hazard ratio of 0.36 and was considered to decrease the risk of developing renal involvement. Based on these findings, patients who have the risk factors for renal involvement should be treated with corticosteroids at the onset of the disease to prevent developing renal involvement.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9607209     DOI: 10.1046/j.1523-1755.1998.00915.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  42 in total

Review 1.  Henoch-Schönlein purpura.

Authors:  E J Tizard
Journal:  Arch Dis Child       Date:  1999-04       Impact factor: 3.791

2.  Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis.

Authors:  Salvatore Li Volti; Giovanni Li Volti
Journal:  Pediatr Nephrol       Date:  2003-09-12       Impact factor: 3.714

Review 3.  Adjuvant treatments for Henoch-Schönlein purpura nephritis in children: A systematic review.

Authors:  Marco Zaffanello; Milena Brugnara; Massimo Franchini; Vassilios Fanos
Journal:  Curr Ther Res Clin Exp       Date:  2009-06

4.  Cyclosporin A therapy for Henoch-Schönlein nephritis with nephrotic-range proteinuria.

Authors:  Jee Min Park; Sung Chul Won; Jae Il Shin; Hyunee Yim; Ki Soo Pai
Journal:  Pediatr Nephrol       Date:  2010-12-24       Impact factor: 3.714

Review 5.  Gastrointestinal manifestations of Henoch-Schonlein Purpura.

Authors:  Ellen C Ebert
Journal:  Dig Dis Sci       Date:  2008-03-20       Impact factor: 3.199

Review 6.  Treatment-based literature of Henoch-Schönlein purpura nephritis in childhood.

Authors:  Marco Zaffanello; Vassilios Fanos
Journal:  Pediatr Nephrol       Date:  2008-12-09       Impact factor: 3.714

7.  Establishing hospital admission criteria of pediatric Henoch-Schonlein purpura.

Authors:  Kamal Masarweh; Yoseph Horovitz; Avi Avital; Ronen Spiegel
Journal:  Rheumatol Int       Date:  2014-02-23       Impact factor: 2.631

8.  Obesity increases the risk of renal involvement in children with Henoch-Schönlein purpura.

Authors:  Yong-Li Zhao; Zheng-Juan Liu; Xue-Mei Bai; Yu-Chuan Wang; Guo-Hua Li; Xue-Yan Yan
Journal:  Eur J Pediatr       Date:  2015-04-22       Impact factor: 3.183

9.  Treatment of complicated henoch-schönlein purpura with mycophenolate mofetil: a retrospective case series report.

Authors:  A A Nikibakhsh; H Mahmoodzadeh; M Karamyyar; S Hejazi; M Noroozi; A A Macooie; A Gholizadeh; L Gholizadeh
Journal:  Int J Rheumatol       Date:  2010-06-15

10.  Predictive factors of renal involvement or relapsing disease in children with Henoch-Schönlein purpura.

Authors:  Donato Rigante; Marcello Candelli; Gilda Federico; Francesco Bartolozzi; Maria Grazia Porri; Achille Stabile
Journal:  Rheumatol Int       Date:  2004-03-06       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.